Abcodia

Abcodia is a company that focuses on biomarkers for cancer screening. Its aim is to discover biomarkers that can be used for the early detection of cancer.
Disease focus.
Abcodia's primary focus is the study of biomarkers for cancer.
Cancer screening.
On 18 September 2013 Abcodia announced that it had entered into an agreement for an exclusive license for the Risk of Ovarian Cancer Algorithm (ROCA), a test studied for screening of ovarian cancer. The use of this test is not recommended by the FDA as there is no evidence it is either safe or effective.
History.
Abcodia is a spin-out from University College London and was founded in 2010. UCL granted Abcodia the exclusive commercialisation rights to a serum collection created by clinical scientists at the Institute for Women's Health at UCL. The serum biobank was formed as part of the UK Collaborative Trial of Ovarian Cancer Screening UKCTOCS, which was led by Professor Ian Jacobs and Professor Usha Menon. 
Awards.
December 2012, Abcodia won four prizes at the UK Startup Awards 2012 annual awards: Angel or VC-backed Business of the Year, Innovative Business of the Year, and Business Woman of the Year for its CEO Dr Julie Barnes. It also won the overall NatWest Startups Business of the Year for its work in cancer screening.
U.S. General Stanley McChrystal said he was "extremely saddened". "I have made it clear to our forces that we are here to protect the Afghan people, and inadvertently killing or injuring civilians undermines their trust and confidence in our mission," he said in a statement. "We will re-double our efforts to regain that trust."
Netherlands.
A Dutch Defense Ministry spokesman in The Hague said Dutch forces did not call the airstrike, which took place in an area under Dutch military control.